The AIDS Healthcare Foundation is urging the drugmaker to change its pricing and access policies in a series of ads, called “Shame on Merck,” that criticize an increase of up to six times the price of its AIDS drug Stocrin in Mexico than in other Latin American countries.

“We want to make policy makers and the public-at-largeincluding Merck’s employees and New Jersey neighborsaware of the striking inequity in Merck’s corporate policies regarding its pricing of Stocrin in Mexico,” Michael Weinstein, the organization’s president, in a statement.

The foundation argues that AIDS drugs can cost as little as $150 in what are designated less developed countries or low income countries in Africa, can coast as much as $8,000 in Mexico, where per capita income is roughly $7,310, meaning 9.5 percent more than an average person’s income.

The group also says that it has been nearly two years since Merck announced its agreement with Gilead to distribute Atripla in Mexico for $1,032 per patient annually, but that apparently hasn’t occured, and Mexicans are paying more than $4,300 for the same three meds separately.